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Summary
Background Poly(ADP-ribose) polymerase (PARP) inhibitors have antitumour activity against metastatic castration-
resistant prostate cancers with DNA damage response (DDR) alterations in genes involved directly or indirectly in 
homologous recombination repair (HRR). In this study, we assessed the PARP inhibitor talazoparib in metastatic 
castration-resistant prostate cancers with DDR-HRR alterations.
Methods In this open-label, phase 2 trial (TALAPRO-1), participants were recruited from 43 hospitals, 
cancer centres, and medical centres in Australia, Austria, Belgium, Brazil, France, Germany, Hungary, Italy, the 
Netherlands, Poland, Spain, South Korea, the UK, and the USA. Patients were eligible if they were men aged 18 years or 
older with progressive, metastatic, castration-resistant prostate cancers of adenocarcinoma histology, measurable soft-
tissue disease (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]), an Eastern Cooperative 
Oncology Group performance status of 0–2, DDR-HRR gene alterations reported to sensitise to PARP inhibitors 
(ie, ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C), had received one or 
two taxane-based chemotherapy regimens for metastatic disease, and progressed on enzalutamide or abiraterone, 
or both, for metastatic castration-resistant prostate cancers. Eligible patients were given oral talazoparib (1 mg per day; or 
0·75 mg per day in patients with moderate renal impairment) until disease progression, unacceptable toxicity, investigator 
decision, withdrawal of consent, or death. The primary endpoint was confirmed objective response rate, defined as best 
overall soft-tissue response of complete or partial response per RECIST 1.1, by blinded independent central review. The 
primary endpoint was assessed in patients who received study drug, had measurable soft-tissue disease, and had a gene 
alteration in one of the predefined DDR-HRR genes. Safety was assessed in all patients who received at least one dose of 
the study drug. This study is registered with ClinicalTrials.gov, NCT03148795, and is ongoing.
Findings Between Oct 18, 2017, and March 20, 2020, 128 patients were enrolled, of whom 127 received at least one dose 
of talazoparib (safety population) and 104 had measurable soft-tissue disease (antitumour activity population). Data 
cutoff for this analysis was Sept 4, 2020. After a median follow-up of 16·4 months (IQR 11·1–22·1), the objective 
response rate was 29·8% (31 of 104 patients; 95% CI 21·2–39·6). The most common grade 3–4 treatment-emergent 
adverse events were anaemia (39 [31%] of 127 patients), thrombocytopenia (11 [9%]), and neutropenia (ten [8%]). Serious 
treatment-emergent adverse events were reported in 43 (34%) patients. There were no treatment-related deaths.
Interpretation Talazoparib showed durable antitumour activity in men with advanced metastatic castration-resistant 
prostate cancers with DDR-HRR gene alterations who had been heavily pretreated. The favourable benefit–risk profile 
supports the study of talazoparib in larger, randomised clinical trials, including in patients with non-BRCA alterations.
Funding Pfizer/Medivation.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Introduction
The poly(ADP-ribose) polymerase (PARP) enzymes 
PARP1 and PARP2 are key components of the DNA 
damage response (DDR) mechanism.1 PARP inhibitors 
selectively kill specific cancer cells via so-called 
synthetic lethality, a mechanism whereby deficiency in 
function of one gene or gene product has little effect 
alone but is toxic in combination with deficiency in 
function of a second gene or gene product.1 PARP 
inhibition is synthetically lethal in cells with homo-
zygous deletions or deleterious alterations, or both, in 
DDR genes involved either directly or indirectly in 
homologous recombination repair (HRR).1 Germline 
or somatic DDR alterations occur in 23–27% of men 
with prostate cancer,2,3 and are associated with worse 
outcomes.4–6
Talazoparib potently inhibits PARP catalytic activity and 
is the most efficient PARP inhibitor at trapping PARP1 
and PARP2 on DNA single-strand break sites, preventing 
DNA replication and transcription, and leading to 
double-strand DNA breaks and cell death.7–10 Talazoparib is 
approved for treating germline BRCA1-mutated and 
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BRCA2-mutated human epidermal growth factor 
receptor 2 (HER2, ErbB-2) negative metastatic or locally 
advanced breast cancer.11,12 To our knowledge, TALAPRO-1 
is the first international phase 2 trial to assess the 
antitumour activity and tolerability of talazoparib 
monotherapy in men with metastatic castration-resistant 
prostate cancers and HRR gene alterations who have been 
heavily pretreated.
Methods
Study design and participants
TALAPRO-1 is an open-label, phase 2 trial that enrolled 
patients at 43 hospitals, cancer centres, and medical 
centres in 14 countries (Australia, Austria, Belgium, Brazil, 
France, Germany, Hungary, Italy, the Netherlands, Poland, 
Spain, South Korea, the UK, and the USA). Patients were 
eligible if they were men aged 18 years or older with 
progressive metastatic castration-resistant prostate cancers 
of adenocarcinoma histology. Progressive disease was 
defined as a minimum of three increasing prostate-specific 
antigen (PSA) values with an interval of at least 1 week 
between readings, soft-tissue disease progression as 
defined by Response Evaluation Criteria in Solid Tumors 
version 1.1 (RECIST 1.1), or bone disease progression 
defined by Prostate Cancer Working Group 3 criteria13 with 
two or more new metastatic lesions on bone scan. The 
screening central laboratory PSA value needed to be 2 µg/L 
or higher if the candidate was qualifying solely by PSA 
progression. Study inclusion criteria were amended after 
initiation. The original study design allowed the enrolment 
of patients with measurable and non-measurable disease 
in two over lapping cohorts: cohort A, which included 
patients with alterations in HRR likely to sensitise to PARP 
inhibition, and cohort B, which included patients with 
DNA defects in an expanded panel of genes that are likely 
to, or might, sensitise to PARP inhibition. With the 
approval of protocol amend ment three on Feb 15, 2018, 
enrolment was restricted to patients with measurable 
disease and with DNA alter ations likely to sensitise to 
PARP inhibition, which originally comprised a panel of 
13 genes. FANCD2 and FANCI did not pass subsequent 
validation requirements, leaving the following panel of 
11 HRR genes that were used in the analyses: ATM, ATR, 
BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, 
PALB2, and RAD51C. More information is in the appendix 
(p 3). Other inclusion criteria were an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0–2; 
bilateral orchiectomy or ongoing androgen deprivation 
Research in context
Evidence before this study
In the planning phase for TALAPRO-1, we searched PubMed in 
late 2015 to early 2016 for relevant preclinical or clinical research 
published on so-called BRCAness, DNA damage response, DNA 
damage repair (DDR), homologous recombination repair (HRR), 
synthetic lethality, poly(ADP-ribose) polymerase (PARP) 
inhibitors, and advanced prostate cancer. Prostate cancer remains 
the second most common cause of cancer-related death in men, 
with no curative treatment options available once patients 
develop metastatic castration-resistant prostate cancer. At study 
initiation, treatment options for men with metastatic castration-
resistant prostate cancers included novel hormonal therapies 
(eg, enzalutamide, abiraterone), taxanes (docetaxel, cabazitaxel), 
radium-223, and sipuleucel-T. An unmet medical need remains 
for men with metastatic castration-resistant prostate cancers 
who have already received novel hormone therapy and taxane-
based chemotherapy; some of these tumours carry alterations in 
DDR genes involved directly or indirectly in HRR that can sensitise 
to PARP inhibitors. Those alterations have been linked to worse 
prognosis. Several PARP inhibitors are being assessed for the 
treatment of metastatic castration-resistant prostate cancers 
with defective HRR gene alterations. The toxicity profile and 
efficacy or duration of sensitivity to PARP inhibitors might differ 
depending on specific HRR gene alterations; therefore, continued 
research with PARP inhibitors is warranted.
Added value of this study
To our knowledge, this study is the first international phase 2 
trial to assess the antitumour activity and tolerability of 
talazoparib in men with metastatic castration-resistant 
prostate cancers with alterations in DDR genes involved in HRR 
who have been heavily pretreated. Antitumour activity was 
most notable against tumours with BRCA2 alterations, 
although partial or complete responses, stable disease, and 
prostate-specific antigen responses were also seen in tumours 
with alterations in BRCA1, PALB2, and ATM, which affirms that 
PARP inhibition has antitumour activity beyond the BRCA1 and 
BRCA2 subset. Our finding that homozygous loss is associated 
with enhanced antitumour activity might be crucial to 
interpreting antitumour activity results in gene-by-gene 
analyses from prostate cancer PARP inhibitor studies using 
multi-gene panels, including the TALAPRO-1 study.
Implications of all the available evidence
These data suggest that talazoparib has durable antitumour 
activity against lethal prostate cancers with various DNA 
repair defects that directly or indirectly impact HRR. This 
antitumour activity was observed even in men with very 
advanced prostate cancer who have exhausted most available 
treatment options. The favourable benefit–risk profile of 
talazoparib monotherapy against metastatic castration-
resistant prostate cancers with alterations in DDR genes 
either directly or indirectly involved in HRR in men previously 
treated with taxanes and novel hormone therapy supports 
the study of talazoparib in larger, randomised clinical trials, 
including in men with non-BRCA alterations.
See Online for appendix
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therapy with a gonadotropin-releasing hormone agonist or 
antagonist, with serum testosterone of 50 ng/dL or less 
(≤1·73 nmol/L) at screening; stable bisphosphonate or 
denosumab dose for at least 4 weeks for patients receiving 
these therapies; estimated life expectancy of at least 
6 months (as assessed by investigator); and previous treat-
ment with one or two chemotherapy regimens (≥1 taxane-
based) in the metastatic setting (castration-sensitive or 
castration-resistant prostate cancer; patients could have 
received radium-233 or cabazitaxel, or both) and progressed 
on at least one novel hormone therapy (enzalutamide, 
abiraterone, or both) given for metastatic castration-
resistant prostate cancers. A list of key eligibility criteria is 
in the appendix (p 4) and a full list in the protocol 
(appendix).
This study followed Good Clinical Practice standards, 
the Declaration of Helsinki, and the International 
Conference on Harmonisation. The Institutional Review 
Board or Ethics Committee at each study site approved the 
protocol. All patients provided signed informed consent.
Procedures
Potentially eligible patients were screened for the 
prespecified alterations in DDR genes involved directly or 
indirectly in HRR (ie, DDR-HRR genes) that are likely to 
sensitise to PARP inhibition using tumour tissue analysis 
(FoundationOne CDx next-generation sequencing, 
Illumina HiSeq 4000 platform at Foundation Medicine, 
Cambridge, MA, USA) or, if enrolled under protocol 
amendment one (March 31, 2017; amendment allowed the 
entry of men without measurable disease), for HRR 
deficiencies assessed using an expanded DNA damage 
repair panel of genes likely to or that might sensitise to 
PARP inhibition. The gene or genes altered were reported 
using FoundationOne CDx results generated either on 
screening for the study or using historical medical records.
Patients were given oral talazoparib 1 mg per day (or 
0·75 mg per day for patients with moderate renal impair-
ment, defined as an estimated glomerular filtration rate of 
30–59 mL/min per 1·73 m²), with dose modification or 
appropriate supportive care, or both, given for recovery 
from grade 3 or 4 adverse events (appendix pp 5–8). 
Talazoparib was continued until progression, as deter-
mined on radiographic imaging, unacceptable toxicity, 
investigator decision, withdrawal of consent, or death. 
Increased PSA or circulating tumour cell counts alone 
were not a reason for discontinuing talazoparib.
Radiographic assessments (CT [preferred] or MRI of 
the abdomen and pelvis, CT of chest, and whole-body 
radionuclide bone scan) were done every 8 weeks during 
the first 24 weeks, then every 12 weeks thereafter. Soft-
tissue responses were confirmed at least 4 weeks after the 
response was identified with CT or MRI, per RECIST 1.1 
with no evidence of confirmed bone progression per 
Prostate Cancer Working Group 3 criteria on repeat bone 
scan at least 6 weeks later, per independent central review. 
Clinical laboratory tests and assessments of safety were 
done at screening and at each scheduled visit (every 
2 weeks up to week 9, every 4 weeks up to week 25, then 
every 12 weeks thereafter [haematology and serum 
chemistry every 8 weeks] while on study drug). Safety 
assessments included investigator-assessed adverse 
events, physical examinations, vital signs, clinical 
laboratory tests, incidence of dose modifications, and 
permanent treatment discontinuation due to adverse 
events.
Adverse events were coded using the Medical 
Dictionary for Regulatory Activities (version 23.0) and 
classified by severity using the Common Terminology 
Criteria for Adverse Events (version 4.03).
Routine clinical laboratory tests (haematology [using 
electronic cell counter], serum chemistry [using an 
automated chemistry analyser]) were done according to 
protocol-defined timelines by the central laboratory 
(Global Q2 Solutions, a Quintiles Quest Joint Venture, 
Affiliate Labs, Morrisville, NC, USA) but could also be 
collected at any time at the investigator’s discretion or to 
monitor adverse events or determine if dosing 
modifications were required. Circulating tumour cell 
counts were done using the CELLSEARCH platform at 
The Institute of Cancer Research, Sutton, UK. Local safety 
laboratory assessments could also be done but were not to 
replace central laboratory assess ments. Haematology 
assessments included haematocrit, haemoglobin, mean 
corpuscular volume, red blood cell count, platelet count, 
white blood cell count and differential, total neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils; 
chemistry assessments included albumin, total protein 
alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase, total bilirubin, blood urea nitrogen, 
creatinine, glucose (non-fasting), bicarbonate, calcium 
(and calcium albumin corrected), chloride, magnesium, 
phosphate, potassium, sodium, lactate dehydrogenase, 
and PSA.
Germline versus somatic categorisation of alterations 
was based on comparison of tumour and matched saliva 
DNA sequences, and zygosity of alterations was predicted 
centrally using the somatic-germline-zygosity compu-
tational algorithm.14 When patients had multiple alter-
ations of the 11 predefined DDR-HRR genes, for purposes 
of subject-level categorisation, homozygous status was 
considered to be dominant to heterozygous status, and 
germline origin was considered to be dominant to somatic 
origin. Baseline saliva samples were sequenced using the 
Ambry CustomNext-Cancer panel (Ambry Genetics, 
Aliso Viejo, CA, USA), which included nine of the 
11 genes; ATR and FANCA were not present in the 
germline panel. Serial circulating tumour cells, circulating 
tumour DNA, and protein biomarker samples were also 
collected. Circulating tumour DNA analyses will be 
reported separately. Tumour HRR gene alterations were 
designated as being of germline (also present in saliva), 
somatic (tumour only), or unknown origin (core gene not 
represented in the nine-gene germline panel or saliva 
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sample not available or evaluable). This analysis was 
confined to short variants (ie, single-nucleotide variants or 
short insertions or deletions). We did a similar analysis 
using zygosity as assessed using the somatic-germline-
zygosity computational algorithm, which predicts whether 
alterations are homozygous or hemi zygous (hereafter 
referred to as homozygous) or heterozygous, with analysis 
limited to short variants and tumours with adequate 
tumour purity.14
Outcomes
The primary endpoint was confirmed objective response 
rate, defined as best overall soft-tissue response of 
complete or partial response per RECIST 1.1 as assessed 
by blinded independent central review and investigator 
assessment. Secondary endpoints were time to objective 
response (defined as time from the first dose of 
talazoparib to first objective evidence of soft-tissue 
response with no evidence of confirmed bone disease 
progression per Prostate Cancer Working Group 3 
criteria according to blinded inde pendent central review 
and investigator assessment), duration of objective 
response (defined as time from first objective response 
to first objective evidence of radiographic progression or 
death due to any cause per blinded independent central 
review and investigator assessment), proportion of 
patients with a decrease in PSA of 50% or more from 
baseline, time to PSA progression (the time from first 
dose of talazoparib to the date of a ≥25% increase in PSA 
with an absolute increase of ≥2 μg/L [2 ng/mL], 
confirmed by a second consecutive PSA value at 
≥3 weeks later), proportion of patients with conversion 
of circulating tumour cell count (proportion with a 
decrease from baseline of ≥5 to <5 cells per 7·5 mL blood 
or a decrease from ≥1 to 0 cells per 7·5 mL blood at any 
time, or any increase from <5 cells per 7·5 mL blood), 
radiographic progression-free survival (time from the 
first dose of talazoparib to progression in soft tissue as 
determined by radiography per RECIST 1.1, per blinded 
independent central review and investigator assessment, 
in bone as per Prostate Cancer Working Group 3 criteria 
and independent central review, or death due to any 
cause, whichever occurred first), overall survival (time 
from first dose of talazoparib to death due to any cause), 
safety, patient-reported outcomes (time to deterioration 
in patient-reported pain, as assessed by the Brief Pain 
Inventory Short Form [BPI-SF]; change from baseline in 
patient-reported pain as per BPI-SF, and change 
from baseline in patient-reported outcome general 
health status, as assessed by the EQ-5D-5L; all to be 
reported separately), and pharmacokinetics of talazo-
parib (including pre-dose trough and post-dose plasma 
concentrations; to be reported separately).
Potential biomarkers (including HRR gene alteration 
group, HRR gene alteration origin [germline vs somatic], 
and zygosity) of response (including confirmed objective 
response rate, time to objective response, duration of 
response, reduction in tumour burden, PSA, and 
radiographic progression-free survival) were exploratory 
endpoints.
Statistical analysis
The primary aim of TALAPRO-1 was to assess the anti-
tumour activity of talazoparib in terms of objective 
response rate. A planned sample size of at least 
100 patients was sufficient to show that if the observed 
best objective response rate was at least 23%, the lower 
bound of the corresponding exact two-sided 95% CI 
would be higher than 15·2%.
Prespecified interim analyses for safety and antitumour 
activity were planned: after 20 patients who were HRR 
deficient with measurable disease had completed 8 weeks 
of treatment; after 20 patients with BRCA1, BRCA2, or 
PALB2 alterations and measurable disease had received 
study treatment for at least 16 weeks or were no longer 
being followed up (eg, had withdrawn consent, 
discontinued from the study, died, or were otherwise lost 
to follow-up); and after 60 patients who were HRR 
deficient and had measurable disease had completed at 
least 6 months of study treatment or were otherwise no 
longer being followed up (eg, had withdrawn consent, 
discontinued from the study, died, or were otherwise lost 
to follow-up). These analyses are not reported here. We 
did a final analysis, reported herein, after 100 patients 
who were HRR deficient and had measurable disease 
had completed at least 6 months of study treatment or 
were otherwise no longer being followed up (eg, had 
withdrawn consent, discontinued from the study, died, 
or were otherwise lost to follow-up.
The population of patients evaluable for antitumour 
activity was defined as all enrolled patients who had 
measurable soft-tissue disease at screening per investi-
gator assessment, had alterations in a gene within the 
11 predefined DDR-HRR genes, and had received at least 
one dose of talazoparib. Patients with measurable disease 
at baseline and at least one valid assessment after baseline, 
per blinded independent central review, were assessed for 
best change from baseline in the sum of the diameter of 
the target lesions (as part of the objective response rate 
outcome). Post hoc, we analysed all antitumour activity 
endpoints by HRR gene alteration group (BRCA1, BRCA2, 
PALB2, ATM, and the other genes in the predefined panel 
of 11 DDR-HRR genes), in which we separated all patients 
by DDR-HRR gene alteration using a hierarchical strategy, 
with BRCA1 or BRCA2 ranked above PALB2, PALB2 
ranked above ATM, and ATM ranked above all other 
alterations. For analyses, we grouped together the BRCA1 
and BRCA2 groups due to the low number of patients 
with BRCA1 alterations and we anticipated similar 
functional effect of these two alterations on HRR on the 
basis of the scientific literature. We implemented this 
strategy post hoc on the basis of the latest understanding 
of the likely relative importance of these genes.15 We used 
the Brookmeyer and Crowley method to calculate 95% CIs 
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of median radiographic progression-free survival and 
overall survival. We also analysed objective response rates 
for single and co-occurring alterations and by alteration 
origin separately using the two-sided Fisher’s exact test 
and calculated odds ratios (ORs) for objective response. In 
an exploratory analysis of the association of overall and 
objective response with zygosity, an OR of more than 1 
indicated a better outcome for homozygous compared 
with heterozygous status. We calculated the exact CI and 
the p value on the basis of the Fisher’s exact test.
We summarised the rates of binary proportions along 
with two-sided exact 95% CI (Clopper-Pearson method).16 
We summarised time-to-event endpoints using the 
Kaplan-Meier method. We did post-hoc analyses of PSA 
response of ≥30%, composite response (defined as 
objective response, PSA response of ≥50%, or circulating 
tumour cell conversion, or a combination of these 
responses) and objective response rate by blinded 
independent central review according to the presence of 
visceral liver, visceral non-liver, visceral, and non-visceral 
disease (Clopper-Pearson method used for 95% CI). We 
did subgroup analyses of objective response rate by 
blinded independent central review and PSA response, 
with subgroups defined by ECOG performance status, 
geographical region, alteration type, alteration origin, 
zygosity, initial metastatic stage, disease site, previous 
taxane use, and age. Circulating tumour cell count 
conversion rate was defined as any decrease from 5 or 
more cells per 7·5 mL at baseline to less than 5 cells per 
7·5 mL after baseline. Patients with a circulating tumour 
cell count of less than 5 cells per 7·5 mL of blood at 
baseline were not analysed for this conversion endpoint. 
We calculated the proportion of patients with a conversion 
to less than 5 cells per 7·5 mL along with the two-sided 
95% CI using the Clopper-Pearson method (exact CI for a 
binomial proportion). As a post-hoc analysis, clinical 
benefit was defined as complete or partial response, or 
stable disease for at least 6 months from start of treatment.
We did a sensitivity analysis to assess concordance 
between blinded independent central review and investi-
gator assessment using the agreement rate between best 
overall response in the DDR deficient measurable disease 
population.
The safety population was defined as all patients who 
received at least one dose of talazoparib, including a 
subset of patients with non-measurable disease who 
were enrolled under an early version of the protocol and 
HRR gene alterations that were assessed using an 
expanded DDR-HRR gene panel including genes likely 
to or that might sensitise to PARP inhibitors.
Unless otherwise specified, all data were assessed as 
observed and no imputation method was used for missing 
values. Missing dates were imputed per protocol. p values 
of less than 0·05 were considered to be significant. We did 
statistical analyses using SAS version 9.4. This study is 
registered with ClinicalTrials.gov (NCT03148795).
Role of the funding source
The sponsor (Pfizer/Medivation) was involved in study 
design, data analysis, and data interpretation, and 
provided funding for medical writing support. All 
authors, including those employed by the sponsor, 
contributed to data interpretation, develop ment, writing, 
and approval of the manuscript.
Results
The first patient’s first visit occurred on July 4, 2017, with 
prescreening ending on Feb 21, 2020; study enrolment 
officially closed on March 20, 2020. Of 1425 screened 
patients, 1297 did not have HRR gene alterations or did 
not meet other eligibility criteria (figure 1; appendix p 3). 
Between Oct 18, 2017, and March 20, 2020, 128 men were 
enrolled, of whom 23 (18%) had non-measurable disease 
or were not HRR deficient and one (1%) patient did not 
receive talazoparib, leaving 127 patients in the safety 
population (with both measurable and non-measurable 
1425 patients screened
128 enrolled
127 received at least one dose of study drug (safety population)
 104 had HRR-deficient measurable disease (antitumour activity
 population)
 52 BRCA2 gene alteration alone
 15 ATM gene alteration alone
 4 BRCA1 gene alteration alone
 4 PALB2 gene alteration alone 
 22 other HRR gene alteration alone 
 7 had co-occurring HRR gene alterations
30 patients in the safety population on treatment at data cutoff
97 discontinued treatment in the safety population
 5 adverse events
 6 died
 62 disease progression
 1 patient withdrawal
 6 global deterioration of health status
 2 no longer clinically benefitting from treatment
 15 other reasons
28 patients in the antitumour activity population on treatment at 
 data cutoff 
76 discontinued treatment in the antitumour activity population
 3 adverse events
 5 died
 52 disease progression
 1 patient withdrawal
 3 global deterioration of health status
 2 no longer clinically benefitting from treatment
 10 other reasons
1264 did not pass prescreening
 33 did not pass screening
1 not treated
Figure 1: Trial profile
HRR=homologous recombination repair.
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disease) and 104 patients in the antitumour activity 
population (with HRR deficient measurable disease only; 
figure 1). Baseline patient characteristics in the safety and 
antitumour activity populations were similar (table 1). 
Median follow-up was 16·4 months (IQR 11·1–22·1). Data 
cutoff for these analyses was Sept 4, 2020.
Of 104 patients in the antitumour activity population, 




Antitumour activity population (n=104)
BRCA1 or BRCA2 
(n=61)*
BRCA2 (n=57)* PALB2 (n=4) ATM (n=17)† Other (n=22)‡ Total (N=104)
Age, years 69·0 (63·0–74·0) 69·0 (63·0–72·0) 69·0 (46·0–83·0) 72·5 (60·5–77·0) 67·0 (61·0–73·0) 71·0 (65·0–79·0) 69·0 (63·0–73·0)
Race
White 110 (87%) 53 (87%) 50 (88%) 3 (75%) 16 (94%) 19 (86%) 91 (88%)
Black 4 (3%) 3 (5%) 3 (5%) 0 0 0 3 (3%)
Asian 3 (2%) 0 0 0 1 (6%) 1 (5%) 2 (2%)
Not reported 10 (8%) 5 (8%) 4 (7%) 1 (25%) 0 2 (9%) 8 (8%)
Renal impairment
Normal or mild 105 (83%) 50 (82%) 46 (81%) 4 (100%) 15 (88%) 16 (73%) 85 (82%)
Moderate 22 (17%) 11 (18%) 11 (19%) 0 2 (12%) 6 (27%) 19 (18%)














Baseline testosterone, ng/dL 10·1 (10·1–19·9) 10·1 (10·1–15·8) 10·1 (10·1–15·0) 15·8 (10·0–33·4) 14·1 (10·1–22·2) 10·1 (10·1–20·7) 10·1 (10·1–17·7)
Baseline CTC count, cells per 7·5 mL of blood 5·0 (0·0–41·0) 5·0 (0·0–22·0) 5·0 (0·0–22·0) 13·0 (3·0–490·0) 23·0 (0·0–62·0) 3·5 (1·5–36·5) 5·0 (1·0–38·0)
Total Gleason score
Grade group 1 (≤6) 9 (7%) 4 (7%) 4 (7%) 0 2 (12%) 3 (14%) 9 (9%)
Grade group 2 (3 + 4) and 3 (4 + 3) 39 (31%) 17 (28%) 17 (30%) 0 6 (35%) 8 (36%) 31 (30%)
Grade group 4 (8) and 5 (9–10) 78 (61%) 39 (64%) 35 (61%) 4 (100%) 9 (53%) 11 (50%) 63 (61%)
Not reported 1 (1%) 1 (2%) 1 (2%) 0 0 0 1 (1%)
Initial M stage at primary diagnosis
M0 50 (39%) 26 (43%) 24 (42%) 0 6 (35%) 7 (32%) 39 (38%)
M1 57 (45%) 26 (43%) 25 (44%) 4 (100%) 9 (53%) 9 (41%) 48 (46%)
MX 16 (13%) 7 (11%) 6 (11%) 0 1 (6%) 5 (23%) 13 (13%)
Not reported 4 (3%) 2 (3%) 2 (4%) 0 1 (6%) 1 (5%) 4 (4%)
Disease site
Visceral 41 (32%) 18 (30%) 17 (30%) 3 (75%) 5 (29%) 10 (45%) 36 (35%)
Non-visceral 86 (68%) 43 (70%) 40 (70%) 1 (25%) 12 (71%) 12 (55%) 68 (65%)
ECOG performance status
0 52 (41%) 24 (39%) 22 (39%) 0 8 (47%) 9 (41%) 41 (39%)
1 63 (50%) 31 (51%) 29 (51%) 4 (100%) 8 (47%) 10 (45%) 53 (51%)
2 12 (9%) 6 (10%) 6 (11%) 0 1 (6%) 3 (14%) 10 (10%)
Previous taxane use
Docetaxel only 65 (51%) 35 (57%) 32 (56%) 1 (25%) 9 (53%) 9 (41%) 54 (52%)
Docetaxel and cabazitaxel 61 (48%) 26 (43%) 25 (44%) 3 (75%) 8 (47%) 12 (55%) 49 (47%)
Not reported 1 (1%) 0 0 0 0 1 (5%) 1 (1%)
Previous novel hormone therapy
Abiraterone only 45 (35%) 28 (46%) 27 (47%) 2 (50%) 3 (18%) 4 (18%) 37 (36%)
Enzalutamide only 46 (36%) 20 (33%) 19 (33%) 2 (50%) 8 (47%) 7 (32%) 37 (36%)
Abiraterone and enzalutamide 34 (27%) 12 (20%) 10 (18%) 0 6 (35%) 10 (45%) 28 (27%)
Not reported 2 (2%) 1 (2%) 1 (2%) 0 0 1 (5%) 2 (2%)
Data are median (IQR) or n (%). Patients were separated hierarchically by HRR gene alterations involved either directly or indirectly with HRR, with BRCA1 and BRCA2 ranked above PALB2, PALB2 ranked above 
ATM, and ATM ranked above all other alterations. CTC=circulating tumour cell. ECOG=Eastern Cooperative Oncology Group. HRR=homologous recombination repair. PSA=prostate-specific antigen. *The BRCA1 
or BRCA2 and BRCA2 groups both included two patients with both BRCA2 and PALB2 alterations, one patient with both BRCA2 and ATM alterations, one patient with both BRCA2 and CHEK2 alterations, and one 
patient with both BRCA2 and MLH1 alterations; these patients were not counted or included in the other groups. †The ATM group included one patient with both ATM and FANCA alterations and one patient 
with both ATM and RAD51C alterations. ‡The other group included patients with HRR gene alterations in ATR, CHEK2, FANCA, MLH1, MRE11A, NBN, or RAD51C.
Table 1: Baseline patient characteristics in the safety population and in the antitumour activity population (overall and by HRR gene alteration group)
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BRCA2 gene alteration alone, 15 (14%) had an ATM 
alteration alone, four (4%) had a PALB2 alteration alone, 
and 22 (21%) had other HRR gene alterations (three or 
fewer participants had each of the other gene alterations, 
except CHEK2 [n=9] and MLH [n=4]). Seven (7%) patients 
had co-occurring HRR gene alterations (appendix p 19). 
Table 1 shows the number of patients in each subgroup 
when separated by the predefined hierarchy. Similar 
rates of HRR gene alterations were seen in the safety 
population (data not shown).
Median duration of talazoparib treatment was 
6·1 months (IQR 3·6–10·8) in the safety population 
and 6·2 months (3·6–9·9) in the antitumour activity 
population.
In the antitumour activity population, confirmed 
objective response rate by blinded independent central 
review was 29·8% (95% CI 21·2–39·6), with a response 
occurring in 31 of 104 patients (table 2). Confirmed 
objective response by blinded independent central review 
by hierarchical separation of HRR gene alteration group 
(post-hoc analysis) was seen in 26 (46%) of 57 patients 
with BRCA2 alterations, two (50%) of four with BRCA1 
alterations, one (25%) of four with PALB2 alterations, and 
two (12%) of 17 with ATM alterations (table 2). Objective 
response rate by individual gene alteration (post hoc) is 
shown in the appendix (p 9). Prespecified subgroup 
analyses for objective response rate by blinded inde-
pendent central review are shown in the appendix (p 20). 
In post-hoc analyses, confirmed objective response by 
blinded independent central review was observed in 
26 (38%) of 68 patients with non-visceral disease and in 
five (14%) of 36 patients with visceral disease. In the 
36 patients with visceral disease, an objective response by 
blinded inde pendent central review was observed in 
one (5%) of 20 patients with liver disease and four (25%) 
of 16 with non-liver disease. Confirmed objective response 
rate by investigator assessment in the antitumour activity 
population was 30·8% (95% CI 22·1–40·6), with 
responses recorded in 32 of 104 patients (appendix 
pp 10–11). The agreement for objective response was 
86·9% (53 of 61 patients) for the BRCA1 and BRCA2 
population and 89·4% overall (93 of 104 patients).
Best change from baseline in sum of diameters for 
target lesions (blinded independent central review), PSA 













Confirmed complete response 6/61 (10%) 6/57 (11%) 0/4 (0%) 1/17 (6%) 0/22 (0%) 7/104 (7%)
Confirmed partial response 22/61 (36%) 20/57 (35%) 1/4 (25%) 1/17 (6%) 0/22 (0%) 24/104 (23%)
Stable disease (any duration) 21/61 (34%) 19/57 (33%) 2/4 (50%) 6/17 (35%) 8/22 (36%) 37/104 (36%)
Stable disease for ≥6 months 6/61 (10%) 6/57 (11%) 0/4 (0%) 2/17 (12%) 0/22 (0%) 8/104 (8%)
Non-complete response or 
non-progressive disease
4/61 (7%) 4/57 (7%) 0/4 (0%) 0/17 (0%) 0/22 (0%) 4/104 (4%)
Progressive disease 4/61 (7%) 4/57 (7%) 0/4 (0%) 8/17 (47%) 10/22 (46%) 22/104 (21%)
Not evaluable 4/61 (7%) 4/57 (7%) 1/4 (25%) 1/17 (6%) 4/22 (18%) 10/104 (10%)
Objective response§ 28/61 (46%) 26/57 (46%) 1/4 (25%) 2/17 (12%) 0/22 (0%) 31/104 (30%)
PSA response of ≥30% (post hoc)¶ 43/61 (70%) 41/57 (72%) 3/4 (75%) 2/17 (12%) 2/22 (9%) 50/104 (48%)
PSA response of ≥50%
In all patients with a baseline and at least 
one post-baseline PSA assessment
39/59 (66%) 37/55 (67%) 3/4 (75%) 1/15 (7%) 1/18 (6%) 44/96 (46%)
In all patients with a baseline PSA 
assessment
39/61 (64%) 37/57 (65%) 3/4 (75%) 1/17 (6%) 1/22 (5%) 44/104 (42%)
CTC conversion from ≥5 to <5 cells per 
7·5 mL of blood||
17/21 (81%) 17/21 (81%) 0/1 (0%) 3/6 (50%) 1/5 (20%) 21/33 (64%)
Median radiographic progression-free 













Composite response (post hoc)†† 44/61 (72%) 42/57 (74%) 3/4 (75%) 4/17 (24%) 2/22 (9%) 53/104 (51%)
Clinical benefit rate (post hoc)§‡‡ 34/61 (56%) 32/57 (56%) 1/4 (25%) 4/17 (24%) 0/22 (0%) 39/104 (38%)
Data are n/N (%), unless otherwise stated. For all endpoints, patients were separated hierarchically by HRR gene alterations involved either directly or indirectly in HRR with 
BRCA1 and BRCA2 ranked above PALB2, PALB2 ranked above ATM, and ATM ranked above all other alterations. CTC=circulating tumour cells. HRR=homologous recombination 
repair. PSA=prostate-specific antigen. *The BRCA1 or BRCA2 and BRCA2 groups included two patients with both BRCA2 and PALB2 alterations, one patient with both BRCA2 and 
ATM alterations, one patient with both BRCA2 and CHEK2 alterations, and one patient with both BRCA2 and MLH1 alterations. †The ATM group included one patient with both 
ATM and FANCA alterations and one patient with both ATM and RAD51C alterations. ‡The other group included patients with HRR gene alterations in ATR, CHEK2, FANCA, MLH1, 
MRE11A, NBN, or RAD51C. §Only includes patients with measurable disease per investigator assessment. ¶PSA response in patients with a baseline PSA assessment. ||Patients 
with a CTC count of ≥5 cells per 7·5 mL of blood at study entry that decreased to <5 cells per 7·5 mL of blood anytime during the study; only includes patients with a baseline CTC 
assessment and ≥1 post-baseline CTC assessment. **Based on the Brookmeyer and Crowley method. ††Defined as patients with objective response, PSA response of ≥50%, or 
CTC conversion, or a combination of these responses. ‡‡Defined as patients with complete response, partial response, or stable disease for ≥6 months from treatment start. 
Table 2: Antitumour activity assessments overall and by HRR gene alteration group, by blinded independent central review, in the antitumour activity 
population
Articles
www.thelancet.com/oncology   Vol 22   September 2021 1257
assessment, and circulating tumour cell counts by HRR 
gene alteration (post-hoc analyses) for the antitumour 
activity population are shown in figure 2. Most patients in 
the antitumour activity population with both baseline and 
post-baseline assessments showed a reduction in tumour 
burden (67 [80%] of 84 patients), PSA level (69 [72%] 
A
PSA response of ≥50%
Zygosity‡
Tumour alteration origin§
CTC conversion from ≥5 to <5 cells
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(Figure 2 continues on next page)
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of 96), and circulating tumour cell count (37 [82%] of 45), 
with the highest rates observed in patients with BRCA1 or 
BRCA2 alterations (47 [90%] of 52 patients for tumour 
burden, 50 [85%] of 59 for PSA, and 26 [93%] of 28 for 
circulating tumour cell count). Most evaluable patients 
with PALB2 or ATM alterations also had a reduction in 
tumour burden, PSA level, and circulating tumour cell 
counts (figure 2). In exploratory analyses, the occurrence 
of some degree of reduction in tumour burden and PSA 
was independent of the DDR-HRR gene alteration, having 
germline or somatic origin, or its zygosity (figure 2). 
However, decreases in tumour size or PSA of 30% or 
more were primarily observed with homozygous alter-
ations (figure 2). Prespecified subgroup analyses for PSA 
response are in the appendix (p 20). Post-hoc analyses of 
PSA response and circulating tumour cell conversion by 
hierarchical separation of HRR gene alteration group are 
in table 2. Post-hoc analyses of the rate of composite 
response and clinical benefit are shown in table 2.
Time to response and duration of response for patients 
with confirmed complete or partial responses by blinded 
independent central review are shown in figure 3A, and 
by investigator assessment are in the appendix (p 22), 
and durations of stable disease are shown in figure 3B. 
In the antitumour activity population, median time to 
objective response was 3·4 months (IQR 1·8–5·4) and 
median duration of response was 12·8 months (95% CI 
6·5 to not evaluable; 12 patients had an ongoing response 
at data cutoff). Time to response and duration of response 
per HRR gene alteration group (post-hoc analyses) by 
blinded independent central review and investigator 
assessment are presented in the appendix (pp 12–13).
63 radiographic progression-free survival events 
occurred. Median radiographic progression-free survival 
by blinded independent central review is shown in 
figure 4 and by HRR gene alteration (post-hoc analyses) 
in the appendix (p 23). Similar results were observed 
for median radiographic progression-free survival by 
C
CTC conversion from ≥5 to <5 cells
per 7·5 mL of blood†
CTC conversion from <5 cells per
7·5mL of blood at baseline that
increased at any time on study†
Clinical benefit¶
CTC conversion from ≥1 to 0 cells











































Figure 2: Best change from baseline in sum of diameters for target lesions by blinded independent central review (A), PSA assessment (B), and CTC count (C) 
in the antitumour activity population
Tumour alteration origin and zygosity were based on tumour tissue samples recorded under the latest screening attempt and assessable for only short variants. All 
analyses exclude patients who did not have baseline or post-baseline assessments. 84 participants were evaluable for sum of diameter for target lesions, 96 patients 
were evaluable for PSA assessment, and 45 were evaluable for CTC count. The other group includes alterations in ATR, CHEK2, FANCA, MLH1, MRE11A, NBN, and 
RAD51C. CTC=circulating tumour cell. HRR=homologous recombination repair. PSA=prostate-specific antigen. *This patient had a BRCA2 rearrangement along with a 
number of other non-HRR alterations associated with prostate cancer pathobiology or negative prognosis, or both, including but not limited to AR amplification, 
TP53 alteration, and HGF amplification. †Only includes patients with a baseline CTC assessment and at least one post-baseline CTC assessment. ‡Predicted DDR-HRR 
gene mutational zygosity. §Patient DDR-HRR alteration origin was based on comparison of tumour with saliva variants. ¶Defined as complete response, partial 
response, or stable disease for at least 6 months from treatment start. ||Bar reaches 2600% but is truncated for display purposes.
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Figure 3: Time to response and duration of response by blinded independent central review in patients with confirmed complete response or partial response 
(n=31; A), and time to stable disease and duration of stable disease in patients with stable disease (n=37; B) in the antitumour activity population
Tumour alteration origin and zygosity were based on tumour tissue samples recorded under the latest screening attempt and assessable only for short variants. 
Some patients were not evaluable for tumour alteration origin and zygosity due to type of alteration (only short variants were amenable to these analyses; hence, 
rearrangements and copy number alterations were excluded), paucity of matched saliva data (tumour alteration origin), or inadequate tumour purity (zygosity), 
or a combination of these factors. HRR gene alteration origins are shown for patients evaluable for both germline (saliva) and tumour HRR gene alteration. 
Alteration zygosity of the 11 predefined DDR-HRR genes was predicted by somatic-germline-zygosity analysis of tumours with adequate purity. The other group 
includes alterations in ATR, CHEK2, FANCA, MLH1, MRE11A, NBN, or RAD51C. HRR=homologous recombination repair.
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investigator assessment (appendix p 24).Median overall 
survival was 16·4 months (95% CI 12·2–19·9; appendix 
p 25) and median time to PSA progression was 
9·2 months (5·6–11·1; appendix p 26). Post-hoc results 
by HRR gene alteration group are shown in the appendix 
(pp 23–26).
In exploratory analyses, 71 men in the antitumour 
activity population were assessable for germline and 
somatic tumour HRR gene alterations, of whom 25 (35%) 
had alterations of germline origin, 44 (62%) had alter-
ations of somatic origin, and five (7%) had alterations of 
unknown origin (ATR and FANCA were not present in 
the germline panel). The most common alterations were 
BRCA2 (13 germline, 19 somatic) and ATM (four germline, 
11 somatic; appendix p 15). Objective responses were 
observed in seven (28%) of 25 men with tumours with 
HRR gene alterations of germline origin and in 11 (26%) 
of 43 men with tumours with HRR gene alterations of 
only somatic origin (p=1·0, two-sided Fisher’s exact test).
92 men in the antitumour activity population had data 
to allow assessment of zygosity, among whom tumour 
HRR gene alterations were predicted to have a loss 
of heterozygosity in 30 (33%) men, heterozygous in 
30 (33%) men, and with zygosity non-evaluable in 
32 (35%) men. Objective response in tumours with HRR 
gene alterations with loss of heterozygosity was observed 
in 12 (40%) of 30 men and for those categorised as 
heterozygous was observed in four (13%) of 30 men 
(OR 4·33 [95% CI 1·06–20·94]; p=0·039). Objective 
response in tumours with evaluable BRCA2 gene 
alterations with loss of heterozygosity was observed in 
nine (50%) of 18 men and for those categorised as 
heterozygous was observed in four (44%) of nine men 
(OR 1·25 [0·19–8·55; p=1·00]). Although the number of 
tumours with ATM alterations was relatively low, tumour 
size reductions were typically associated with homozygous 
alterations (figure 2A).
In the safety population, 121 (95%) of 127 men reported 
any all-cause treatment-emergent adverse event (table 3). 
Anaemia, nausea, decreased appetite, and asthenia were 
the most common all-grade treatment-emergent adverse 
events (table 3). The most common grade 3–4 treatment-
emergent adverse events (ie, occurred in ≥5% patients) 
were anaemia (in 39 [31%] of 127), thrombocytopenia 
(11 [9%]), and neutropenia (ten [8%]; table 3); no grade 4 
anaemia or neutropenia events were observed. 
41 (32%) patients reported grade 3 and five (4%) patients 
reported grade 4 haematological treatment-emergent 
adverse events, and 40 (32%) grade 3 events and four (3%) 
grade 4 events were considered to be treatment related by 
the investigators. All-cause serious treatment-emergent 
adverse events were reported in 43 (34%) of 127 patients 
(appendix p 17). The most common all-cause serious 
adverse events (ie, that occurred in more than one patient) 
were pulmonary embolism (eight [6%]), anaemia 
(five [4%]), disease progression (four [3%]), urinary tract 
infection (three [2%]), pneumonia (three [2%]), and 
general physical health deterioration, pain, pyrexia, 
subdural haematoma, and platelet count decreased (each 
occurred in two [2%] patients). 11 (9%) patients reported 
treatment-related serious adverse events, which were 
anaemia (five [4%]), decreased platelet count (two [2%]), 
and asthenia, pyrexia, decreased white blood cell 
count, pulmonary embolism, and overdose (each 
one [1%] patient; a patient could report more than one 
adverse event). 69 all-cause deaths occurred, of which 
59 (86%) were due to disease progression, two (3%) were 
not related to study treatment, three (4%) were reported 
as due to other reasons, and five (7%) were reported as 
due to unknown causes. Mutliple causes of death could 
be reported for each participant. No deaths were related 
to talazoparib. No patients had myelodysplastic syndrome 
or acute myeloid leukaemia (known treatment-emergent 
adverse events among patients with solid tumours given 
talazoparib11) while on study or by the end of follow-up.
All-cause treatment-emergent adverse events led to 
dose reductions in 33 (26%) of 127 patients and dose 
interruptions in 47 (37%) patients. The most common 
treatment-emergent adverse events leading to dose 
reductions were anaemia (28 [22%] of 127 patients), 
decreased platelet count (six [5%]), decreased neutrophil 
count (four [3%]), and decreased white blood cell count 
(three [2%]). The most common treatment-emergent 
adverse events leading to dose interruptions were 
anaemia (24 [19%]), decreased platelet count (14 [11%]), 
decreased neutrophil count (ten [8%]), and decreased 
appetite (six [5%]). 44 (35%) patients were given at 
least one blood transfusion (appendix p 16). All-cause 
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Overall n=104, events=63, median progression-free survival=5·6 months
(95% CI 3·7–8·8)
BRCA1 or BRCA2 group n=61, events=31, 
median progression-free survival=11·2 months (95% CI 7·5–19·2)
ATM group n=17, events=11, median progression-free survival=3·5 months
(95% CI 1·7–8·3)
Figure 4: Radiographic progression-free survival by HRR gene altered (blinded independent central review; 
antitumour activity population)
We present data for BRCA1 or BRCA2 and ATM alterations because of their mutational prevalence, potential 
differential biology, and variation of response (appendix p 9). HRR=homologous recombination repair.
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discontinuation of talazoparib were reported in 15 (12%) 
of 127 patients; of these discontinuations, three (20%) 
were due to haematological treatment-emergent adverse 
events (two due to decreased platelet count and one due 
to decreased white blood cell count), and one (7%) was 
due to a gastrointestinal treatment-emergent adverse 
event (vomiting). A complete list of adverse events leading 
to discontinuation of talazoparib is in the appendix (p 18).
Discussion
TALAPRO-1 is an open-label, phase 2 trial of single-agent 
talazoparib in men with metastatic castration-resistant 
prostate cancers with alterations of DDR genes involved 
directly or indirectly in HRR and who have been heavily 
pretreated with novel hormone therapy and taxane 
chemotherapy. In this population, talazoparib had robust 
antitumour activity, which was most notable and durable 
against tumours with BRCA1 or BRCA2 gene alterations. 
Responses were also confirmed in patients with tumours 
Grade 1–2 Grade 3 Grade 4
Any treatment-emergent adverse 
event
50 (39%) 57 (45%) 4 (3%)
Non-haematological
Nausea 39 (31%) 3 (2%) 0
Decreased appetite 32 (25%) 4 (3%) 0
Asthenia 25 (20%) 5 (4%) 0
Fatigue 23 (18%) 2 (2%) 0
Constipation 22 (17%) 1 (1%) 0
Diarrhoea 21 (17%) 0 0
Peripheral oedema 20 (16%) 1 (1%) 0
Back pain 16 (13%) 1 (1%) 0
Dyspnoea 15 (12%) 2 (2%) 0
Vomiting 15 (12%) 2 (2%) 0
Dizziness 15 (12%) 0 0
Pain in extremity 10 (8%) 2 (2%) 0
Arthralgia 9 (7%) 1 (1%) 0
Bone pain 8 (6%) 1 (1%) 0
Fall 8 (6%) 1 (1%) 0
Haematuria 8 (6%) 1 (1%) 0
Headache 8 (6%) 1 (1%) 0
Musculoskeletal pain 6 (5%) 3 (2%) 0
Urinary tract infection 7 (6%) 2 (2%) 0
AST increased 6 (5%) 2 (2%) 0
Paraesthesia 7 (6%) 1 (1%) 0
Pulmonary embolism 1 (1%) 6 (5%) 0
ALT increased 6 (5%) 1 (1%) 0
Dysuria 6 (5%) 1 (1%) 0
Hypertension 3 (2%) 4 (3%) 0
Pain 6 (5%) 1 (1%) 0
Chest pain 5 (4%) 1 (1%) 0
Hypotension 5 (4%) 1 (1%) 0
Blood ALP increased 4 (3%) 1 (1%) 0
Cancer pain 2 (2%) 3 (2%) 0
γ-Glutamyltransferase 
increased
2 (2%) 2 (2%) 1 (1%)
Abdominal pain 3 (2%) 1 (1%) 0
Disease progression 0 0 0
Hyponatraemia 2 (2%) 2 (2%) 0
Bronchitis 2 (2%) 1 (1%) 0
Hypophosphataemia 2 (2%) 1 (1%) 0
Muscular weakness 2 (2%) 1 (1%) 0
Pneumonia 0 3 (2%) 0
Toothache 2 (2%) 1 (1%) 0
Blood potassium increased 1 (1%) 1 (1%) 0
(Table 3 continues in next column)
Grade 1–2 Grade 3 Grade 4
(Continued from previous column)
Cataract 1 (1%) 1 (1%) 0
Ecchymosis 1 (1%) 1 (1%) 0
General physical health 
deterioration
0 1 (1%) 0
Hypomagnesaemia 1 (1%) 1 (1%) 0
Spinal cord compression 1 (1%) 1 (1%) 0
Subdural haematoma 0 1 (1%) 0
Blood bilirubin increased 0 1 (1%) 0
Cardiorespiratory arrest 0 0 0
Condition aggravated 0 1 (1%) 0
Gastrointestinal infection 0 1 (1%) 0
Third nerve paresis 0 1 (1%) 0




Metastases to meninges 0 1 (1%) 0
Neoplasm progression 0 0 0
Pancreatic carcinoma 0 1 (1%) 0
Parotitis 0 1 (1%) 0
Penile pain 0 1 (1%) 0
Proctitis 0 1 (1%) 0
Radicular pain 0 1 (1%) 0
SARS-CoV-2 positive test 0 1 (1%) 0
Sepsis 0 0 1 (1%)
Haematological
Any 22 (17%) 41 (32%) 5 (4%)
Anaemia 23 (18%) 39 (31%) 0
Thrombocytopenia 13 (10%) 7 (6%) 4 (3%)
Neutropenia 11 (9%) 10 (8%) 0
Leukopenia 12 (9%) 1 (1%) 0
Lymphopenia 4 (3%) 4 (3%) 2 (2%)
Data are n (%). Data are for events reported in at least 10% of patients for 
grade 1–2 events and all events for grades 3 and 4. Included data up to 28 days 
after the last dose of talazoparib, or before new systemic (ie, not including surgery 
or radiotherapy) antineoplastic therapy, whichever occurs first. Ten grade 5 
treatment emergent adverse events (ie, deaths) occurred: one due to pulmonary 
embolism, four due to disease progression, one due to general physical health 
deterioration, one due to subdural haematoma, one due to cardiorespiratory 
arrest, one due to malignant neoplasm progression, and one due to neoplasm 
progression. MedDRA version 23.0 coding dictionary applied. ALP=alkaline 
phosphatase. ALT=alanine aminotransferase. AST=aspartate aminotransferase. 
MedDRA=Medical Dictionary for Regulatory Activities.
Table 3: All-cause treatment-emergent adverse events in the safety 
population (n=127)
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with alterations in PALB2 alone and ATM alone. Stable 
disease of any duration was observed in patients with 
alterations in PALB2, ATM, and other rarer HRR genes 
(ATR, CHEK2, FANCA, MLH1, MRE11A, NBN, and 
RAD51C).
The results we report here are similar to those reported 
in other PARP inhibitor trials. In the phase 3 PROfound 
trial (NCT02987543) assessing olaparib mono therapy 
versus enzalutamide or abiraterone in men with metastatic 
castration-resistant prostate cancers with an HRR gene 
alteration previously treated with novel hormone therapy—
an earlier disease setting than TALAPRO-1—the objective 
response rate in patients with BRCA1, BRCA2, or ATM 
alterations was 33·3% (28 of 84 patients) for olaparib 
versus 2·3% (one of 43 patients) in the control group.17 
Progression-free survival and overall survival were longer 
with olaparib than with control (median progression-free 
survival: 7·4 months vs 3·6 months; median overall 
survival: 19·1 months vs 14·7 months).17,18 In the phase 2 
TRITON2 trial of rucaparib (NCT02952534), patients with 
metastatic castration-resistant prostate cancer with HRR 
gene alter ations and previously treated with novel hormone 
therapy and taxane chemotherapy had objective response 
rates by gene subgroup of 43·5% (27 of 62 patients) for 
BRCA1 or BRCA2, 10·5% (two of 19 patients) for ATM, 
11·1% (one of nine patients) for CHEK2, and 0% (none of 
ten patients) for CDK12.19,20 Median radiographic 
progression-free survival in men with BRCA1 or BRCA2 
mutations was 9·0 months (95% CI 8·3–13·5) and 
estimated 12-month overall survival was 73·0% (95% CI 
62·9–80·7).20 In the phase 2 Galahad trial of niraparib 
(NCT02854436), involving men with metastatic castration-
resistant prostate cancers with bi-allelic DNA-repair gene 
defects who had been previously treated with novel 
hormone therapy and taxane chemotherapy, the objective 
response rate was 41·4% for the BRCA1 or BRCA2 sub-
group.21 Although antitumour activity data from these 
trials seem to be similar, there are important distinctions 
that should be considered when comparing these data, 
including the method of determining genomic alteration, 
type of DDR-HRR gene alterations eligible for enrolment, 
previous treat ment requirements, and a requirement for 
measurable soft-tissue disease at study entry.
The safety profile observed so far in TALAPRO-1 is 
consistent with the established safety profile of 
talazoparib.22–24 The most commonly reported all-grade 
adverse events included anaemia, nausea, decreased 
appetite, and asthenia. Dose reduction of talazoparib due 
to adverse events occurred in 33 (26%) of 127 patients 
and permanent treatment discontinuation due to adverse 
events occurred in 15 (12%) patients, although rarely for 
haematological adverse events (three [2%] patients).
A previous study suggested that only a small number 
of patients with ATM-mutated metastatic castration-
resistant prostate cancers derive benefit from PARP 
inhibitors.19 Another study reported complete loss of 
ATM occurring in 68 (11%) of 631 patients with advanced 
prostate cancers was associated with increased genomic 
instability and variable sensitivity to PARP inhibitors.25 
We found that some men with ATM-altered metastatic 
castration-resistant prostate cancers benefitted from 
talazoparib with PSA responses and stable disease. 
Further studies are needed to assess whether or not the 
superior PARP trapping of talazoparib in comparison 
with other PARP inhibtor enhances its antitumour 
activity against tumours bearing ATM alterations.
In exploratory analyses, we found that tumours bearing 
HRR gene alterations with loss of heterozygosity were 
more sensitive to talazoparib than heterozygous altered 
tumours. This observation is consistent with reports that 
tumours with bi-allelic BRCA1 or BRCA2 alterations have 
higher homologous recombination deficiency scores than 
tumours without, including for prostate cancer, making 
them more susceptible to PARP inhibitors.26,27 In 
TALAPRO-1, the objective response rates in men with 
tumours with homozygous or heterozygous BRCA2 
alterations were encouraging (nine [50%] of 18 with 
homozygous and four [44%] of nine with heterozygous 
BRCA2 alterations). The one patient who responded in 
the PALB2 group was not evaluable for zygosity, although 
of the two patients who responded in the ATM group 
both exhibited homozygous alterations. The overall 
number of ATM-altered tumours was low and tumour 
size reduction was typically associated with homozygous 
ATM alterations. The association with a better outcome 
for patients with homozygous alterations versus those 
with heterozygous alterations could help explain the 
differential response among patients with alterations in 
different HRR genes. Loss of heterozygosity has been 
observed in approxi mately 70% of BRCA1-mutant and 
BRCA2-mutant prostate tumours,26,28 and in approximately 
half of ATM-mutant prostate tumours.29 PALB2 physically 
tethers BRCA1 to BRCA2 during HRR, and PALB2 bi-
allelic inactivation or loss is associated with homologous 
recombination deficiency that is similar to BRCA2 loss; 
hence, PALB2 alterations potentially have functional 
equivalence to BRCA1 or BRCA2 alterations in 
sensitisation to PARP inhibition.30 ATM alterations have 
more complex effects on HRR than BRCA and PALB2 
alterations, and ATM is also implicated in replication fork 
stability and cell cycle progression.31 We found that 
germline versus somatic origin of HRR alterations had 
no association with response, which is consistent with 
other results.20
Our study has several limitations, including the absence 
of a control group and potential investigator bias due to the 
open-label design. The trial was not designed to assess 
differences across the HRR gene alteration subgroups 
and, given the absence of a control group, whether 
differences between such subgroups are due to differences 
in treatment effect or in prognosis cannot be determined. 
Investigator bias was addressed by using blinded 
independent central review to assess objective response as 
the primary endpoint. Other limitations include the small 
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sample size, the heterogeneity of the study population with 
respect to the different number and types of treatment 
received before talazoparib, and the potential that we did 
not identify all qualifying tumour HRR gene alterations. 
Another limitation is that the exploratory analysis of 
alteration origin and zygosity prediction could only be 
done for short variants; therefore, these results need be 
confirmed in future appropriately powered studies. 
Notably, fewer patients were evaluable for circulating 
tumour cell conversion than for other biomarkers like 
PSA, reflecting logistical challenges related to real-time 
shipment of these time-sensitive samples, coupled with 
shipping delays and a laboratory closure due to the 
COVID-19 pandemic.
In summary, the benefit–risk profile in TALAPRO-1 
suggests that talazoparib might provide an effective therapy 
for advanced metastatic castration-resistant prostate 
cancers with DDR alterations either directly or indirectly 
associated with HRR. We found evidence of durable 
antitumour activity with a favourable benefit–risk profile in 
men who had been pretreated with novel hormone therapy 
and taxane chemotherapy. These results support further 
assessment of talazoparib in the ongoing phase 3 
TALAPRO-2 trial (NCT03395197) comparing talazoparib 
plus enzalutamide as a first-line treatment in men with 
advanced metastatic castration-resistant prostate cancers 
with or without HRR gene alterations32 and the recruiting 
phase 3 TALAPRO-3 trial (NCT04821622) of talazoparib 
plus enzalutamide in men with metastatic castration-
sensitive prostate cancer with HRR gene alterations.
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